Full Press Release Details
Amsterdam, The Netherlands, Nov. 21, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced that it will be hosting an Investor Day and simultaneous webcast in New York City on December 1, 2014, starting at 8:30 a.m. uniQure management will be joined by distinguished guests to discuss the Company's strategy, clinical programs and uniQure's vision of how gene therapy will change the future of medicine.
Date: December 1, 2014
Time: 8:30 a.m. - approx. 12:30 p.m. ET
Venue: InterContinental New York Times Square, 300 W. 44th St., New York City, NY
J rn Aldag, Chief Executive Officer, uniQure
Krystof Bankiewicz, M.D., Ph.D., Professor of Neurosurgery and Neurology, University of California, San Francisco
Eric Goossens, Chief Operating Officer, uniQure
Ricki Lewis, Ph.D., Author and Genetics Expert
Wolfgang Miesbach, M.D., Head, Hemophilia Center, Johann Wolfgang Goethe University Hospital, Frankfurt/Main
Patrick Most, M.D., Professor of Molecular and Translational Cardiology, University of Heidelberg
Harald Petry, Ph.D., Chief Scientific Officer, uniQure
Hans Christian Rohde, Chief Commercial Officer, uniQure
David Schaffer, Ph.D., Professor of Chemical and Biomolecular Engineering, University of California, Berkeley
To access the webcast, log on to http://www.media-server.com/m/p/tfx7rb2k or go to the "Events" section on the "Media" page of uniQure's website, at http://www.uniqure.com/news/calendar-of-events. A replay of the webcast will be available on uniQure's website for at least 30 days following the event.
uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com
Direct: +31 20 240 6100
Main: +31 20 566 7394
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494